Deutsche Bank Reiterates Fair Value Rating for Sarepta Therapeutic (SRPT)
Sarepta Therapeutic (NASDAQ:SRPT)‘s stock had its “fair value” rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Monday, Analyst Ratings.Net reports. They currently have a $213.00 price target on the stock. Deutsche Bank’s price target would suggest a potential upside of 298.28% from the company’s current price.
Sarepta Therapeutic (NASDAQ:SRPT) traded up 2.37% on Monday, hitting $54.745. 1,092,403 shares of the company’s stock traded hands. Sarepta Therapeutic has a one year low of $21.21 and a one year high of $54.42. The stock has a 50-day moving average of $39.10 and a 200-day moving average of $37.3. The company’s market cap is $1.835 billion.
Sarepta Therapeutic (NASDAQ:SRPT) last released its earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.21. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.08 million. The company’s revenue for the quarter was down 73.2% on a year-over-year basis.
Several other analysts have also recently commented on the stock. Analysts at Robert W. Baird reiterated a “buy” rating on shares of Sarepta Therapeutic in a research note to investors on Thursday. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Sarepta Therapeutic in a research note to investors on Thursday, September 26th. They now have a $65.00 price target on the stock. Finally, analysts at Needham & Company reiterated a “positive” rating on shares of Sarepta Therapeutic in a research note to investors on Monday, September 23rd. Seven analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Sarepta Therapeutic currently has a consensus rating of “Buy” and a consensus price target of $68.23.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.